Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Adjuvant Capital is a venture capital firm founded to finance life science technologies that tackle high-burden public health challenges. Based in New York City and Zurich, the firm focuses on improving health outcomes in low- and middle-income countries while pursuing financial returns. They primarily invest in preferred equity in technologies that have demonstrated safety and efficacy in humans.
Adjuvant Capital invests in technologies targeting neglected and high-burden infectious diseases, maternal and child health, nutrition, and reproductive and sexual health. The firm typically invests at the seed, Series A, and Series B stages, focusing on technologies with compelling proof-of-concept data and proven safety and efficacy.
Notable portfolio companies include LimmaTech Biologics (vaccine development for antimicrobial resistance), Memo Therapeutics (antibody discovery for viruses), Curevo Vaccine (next-gen vaccines for varicella), and Excision BioTherapeutics (CRISPR therapies for viral infections).
Email yanatos@adjuvantcapital.com with your deck to pitch Adjuvant Capital.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.